Ameritas Investment Partners’s Minerva Neurosciences NERV Stock Holding History

Ameritas Investment Partners’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-276	Closed	-$6K	–	3170
2021 Q1	$6K	Hold	276	–	–	﹤0.01%	2982
2020 Q4	$5K	Hold	276	–	–	﹤0.01%	2976
2020 Q3	$7K	Hold	276	–	–	﹤0.01%	2877
2020 Q2	$8K	Hold	276	–	–	﹤0.01%	2825
2020 Q1	$13K	Hold	276	–	–	﹤0.01%	2400
2019 Q4	$16K	Hold	276	–	–	﹤0.01%	2521
2019 Q3	$17K	Hold	276	–	–	﹤0.01%	2479
2019 Q2	$12K	Hold	276	–	–	﹤0.01%	2726
2019 Q1	$17K	Hold	276	–	–	﹤0.01%	2461
2018 Q4	$15K	Hold	276	–	–	﹤0.01%	2489
2018 Q3	$28K	Hold	276	–	–	﹤0.01%	2336
2018 Q2	$18K	Hold	276	–	–	﹤0.01%	2567
2018 Q1	$14K	Hold	276	–	–	﹤0.01%	2595
2017 Q4	$13K	Hold	276	–	–	﹤0.01%	2660
2017 Q3	$13K	Hold	276	–	–	﹤0.01%	2658
2017 Q2	$20K	Buy	276 +120	+77%	+$7.77K	﹤0.01%	2451
2017 Q1	$10K	Buy	+156	New	+$12.1K	﹤0.01%	2696

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ameritas Investment Partners's NERV Position: Q2 2021 in Review

Ameritas Investment Partners sold out of Minerva Neurosciences (NERV) in Q2 2021, closing a stake of 276 shares — an estimated $6K sold.

Ameritas Investment Partners first reported a position in NERV in Q1 2017 and held it in 17 quarters. The position peaked at $28K in Q3 2018. 68 funds tracked by Wall St. Rank hold NERV as of Q2 2021.

Ameritas Investment Partners reported no remaining Minerva Neurosciences position as of Q2 2021 after selling out during the quarter.
Ameritas Investment Partners sold 276 Minerva Neurosciences shares in Q2 2021, an estimated $6K.
Ameritas Investment Partners first reported a position in Minerva Neurosciences in Q1 2017 and held it in 17 quarters.
Ameritas Investment Partners's Minerva Neurosciences position peaked at $28K in Q3 2018.
68 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2021.

Based on Ameritas Investment Partners's 13F filing for Q2 2021, filed 6 Aug 2021.